UnitedHealthcare, Cigna, and Aetna have all expanded GLP-1 weight management coverage options for employer-sponsored health plans in 2026, a shift driven by growing corporate demand and accumulating evidence that treating obesity reduces total healthcare spending. The three insurers collectively cover more than 140 million Americans, and their decisions are expected to make GLP-1 medications accessible to millions of workers who previously had no coverage for weight management drugs.

The moves represent a significant reversal. As recently as 2024, most large insurers either excluded anti-obesity medications from their standard formularies or offered them only as costly add-on benefits. Employers who wanted to cover GLP-1 drugs for weight loss typically faced premium surcharges of 5-12% [1].

What the Insurers Are Offering

UnitedHealthcare launched a new benefit tier called "Metabolic Health Plus" in January 2026, available to employer groups with 100 or more employees. The tier covers GLP-1 medications (semaglutide and tirzepatide) for weight management with prior authorization requirements, including documented BMI criteria, evidence of prior lifestyle intervention, and mandatory participation in a behavioral counseling program. The premium surcharge for employers ranges from 2-4%, depending on the group's risk profile [2].

Cigna introduced its "Weight Management Rx" benefit in February 2026, structured similarly but with a step-therapy requirement. Patients must first try a lower-cost weight management medication (such as phentermine-topiramate or naltrexone-bupropion) for 90 days before GLP-1 therapy is authorized. Cigna estimates this approach reduces plan costs by 30-40% compared to open GLP-1 access, because a significant percentage of patients respond adequately to first-line medications [3].

Aetna updated its standard commercial formulary in March 2026 to include Wegovy and Zepbound under its specialty pharmacy tier, with a $150-$250 monthly copay for patients, depending on the specific plan design. Previously, Aetna covered these drugs only for diabetes indications. The weight management indication is now available as a standard benefit, though employers can still opt out [4].

Why Employers Are Driving the Change

The shift is coming from the corporate benefits side, not from insurers voluntarily expanding coverage. Human resources executives at major corporations have been pressuring their insurers to add GLP-1 coverage because of three converging factors.

Employee demand is the most immediate driver. A Willis Towers Watson survey of 450 large employers conducted in Q4 2025 found that 67% reported employees specifically requesting GLP-1 coverage for weight management, up from 34% in Q4 2023 [5]. In competitive labor markets, benefits packages influence recruitment and retention.

Healthcare cost data is the strategic driver. Mercer's 2025 National Survey of Employer Health Plans found that obese employees cost an average of $5,530 more per year in medical claims than employees at a healthy weight [6]. Those costs show up in higher utilization across nearly every medical category: musculoskeletal conditions, cardiovascular disease, diabetes, mental health, and disability claims.

The third factor is early evidence from employers who adopted GLP-1 coverage in 2024 and 2025. Several large self-insured employers, including JP Morgan Chase, Amazon, and Walmart, began covering GLP-1 medications in 2024. Internal data from these programs, shared at the Health Transformation Alliance conference in January 2026, showed that total medical spend for enrolled employees decreased by 8-15% within the first year of treatment, offsetting a significant portion of the drug cost [7].

The Cost Equation

The economics of GLP-1 coverage remain challenging. At current list prices of $1,000-$1,350 per month, covering GLP-1 drugs for even a fraction of eligible employees is expensive. An employer with 10,000 employees might see 3-5% of its workforce seek GLP-1 prescriptions, translating to drug costs of $3.6 million to $8.1 million per year.

However, employers and actuaries are increasingly looking at net cost rather than drug cost alone. Dr. Mark Fendrick, director of the University of Michigan Center for Value-Based Insurance Design, has published research showing that when downstream healthcare savings are factored in, the net cost of GLP-1 coverage is substantially lower than the pharmacy expense alone.

"The pharmacy budget goes up, but the medical budget goes down," Dr. Fendrick explained at a Milken Institute panel in February. "Employers who only look at pharmacy spend are seeing half the picture. When you model reduced hospitalizations, fewer surgeries, lower diabetes incidence, and decreased disability claims, the net investment is far more manageable."

Pharmacy benefit managers are also negotiating steeper discounts. Express Scripts reported that its negotiated net price for Wegovy decreased by approximately 25% between 2024 and 2026, reflecting the competitive pressure between Novo Nordisk and Eli Lilly [8].

Prior Authorization Requirements

All three insurers are using prior authorization and utilization management to control costs. Common requirements include documented BMI of 30 or higher, or 27 or higher with a weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Patients generally must demonstrate that they have tried lifestyle modifications, including diet and exercise, for at least 6 months before medication is authorized.

Ongoing authorization typically requires documented follow-up with a healthcare provider every 90 days and evidence of at least 5% body weight loss within the first 6 months of treatment. Patients who do not meet the weight loss threshold may lose coverage unless their prescriber provides clinical justification for continued treatment.

These requirements add administrative burden for prescribers and patients, but they serve a purpose. Without utilization controls, actuaries project that GLP-1 drug spend could consume 5-8% of total employer healthcare budgets, a level that most plan sponsors would find unsustainable [1].

What Employees Should Do

Workers whose employer-sponsored health plan has added GLP-1 coverage should start by reviewing their specific plan documents. Coverage terms vary significantly between employers, even within the same insurer.

Key questions to ask your HR benefits department or call the number on the back of your insurance card: Does my plan cover GLP-1 medications for weight management, or only for diabetes? What prior authorization requirements apply? Which specific medications are covered (Wegovy, Zepbound, or both)? What is my copay or coinsurance amount? Is there a step-therapy requirement? Do I need to use a specialty pharmacy?

Patients who are currently paying out of pocket for GLP-1 medications should check whether their plan has added coverage for 2026, as some employers added the benefit at their January renewal without widely publicizing it.

Dr. Fendrick offered advice for employees whose plans still exclude GLP-1 coverage. "Talk to your HR department. The employers who added coverage did so because their employees asked for it. One request won't change a benefits design, but when HR hears from dozens of employees, it gets on the agenda for the next renewal cycle."

Sources

  1. Mercer. "GLP-1 Coverage Trends in Employer Health Plans." February 2026.
  2. UnitedHealthcare. "Metabolic Health Plus Benefit Overview." January 2026.
  3. Cigna. "Weight Management Rx Program Details." February 2026.
  4. Aetna. "2026 Commercial Formulary Updates." March 2026.
  5. Willis Towers Watson. "2025 Best Practices in Health Care Employer Survey." December 2025.
  6. Mercer. "National Survey of Employer-Sponsored Health Plans 2025." November 2025.
  7. Health Transformation Alliance. "GLP-1 Early Adopter Employer Data." Conference Proceedings, January 2026.
  8. Express Scripts. "Drug Trend Report 2025." February 2026.